December 21, 2016 / 1:13 PM / in 7 months

BRIEF-Azurrx Biopharma enrolls 3 patients in mid-stage study for endocrine ancreatic insufficiency

1 Min Read

Dec 21 (Reuters) - Azurrx Biopharma Inc:

* Azurrx Biopharma announces first three patients included in phase IIa study with ms1819-sd for endocrine pancreatic insufficiency

* Azurrx Biopharma - anticipates reporting results from 1st group of patients enrolled expected to be reported in first half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below